Table of Contents
Overview
New York, NY – July 22, 2025 –The DNA Synthesis Market Size is expected to be worth around USD 13.6 Billion by 2033 from USD 3.2 Billion in 2023, growing at a CAGR of 15.5% during the forecast period 2024 to 2033.
DNA synthesis refers to the artificial creation of deoxyribonucleic acid (DNA) sequences in a laboratory setting. This critical process forms the foundation of numerous advances in genetics, synthetic biology, and biotechnology. At its core, DNA synthesis involves assembling nucleotide bases adenine (A), thymine (T), cytosine (C), and guanine (G) in a specific sequence to replicate or design new strands of DNA. These sequences may correspond to natural genes or be entirely synthetic, designed for targeted research or therapeutic purposes.
Modern DNA synthesis techniques, such as solid-phase phosphoramidite synthesis, allow for precise and scalable production of custom DNA strands. This capability has accelerated developments in gene editing, vaccine development, agricultural engineering, and diagnostic tools. For example, synthetic DNA plays a key role in the production of mRNA vaccines and in the engineering of CRISPR-Cas9 gene editing components.
The growing demand for DNA synthesis is driven by its potential to solve complex biological problems, enable rapid prototyping of biological systems, and support personalized medicine. As synthesis costs continue to decline and accuracy improves, the technology is becoming more accessible to academic institutions, biotech startups, and pharmaceutical companies worldwide.
DNA synthesis is not only transforming scientific research but also redefining the future of medicine, agriculture, and environmental sustainability, marking a new era of innovation in life sciences.
Key Takeaways
- In 2023, the global DNA synthesis market generated revenue of USD 3.2 billion and is projected to reach USD 13.6 billion by 2033, expanding at a robust CAGR of 15.5% during the forecast period.
- By service type, the market is segmented into oligonucleotide synthesis and gene synthesis, which further includes subcategories such as standard and custom oligonucleotide synthesis, custom gene synthesis, and gene library synthesis. Oligonucleotide synthesis emerged as the leading segment in 2023, accounting for a dominant market share of 54.8%.
- Based on synthesis methods, the market is categorized into solid phase synthesis, PCR-based enzyme synthesis, and chip-based DNA synthesis. Among these, solid phase synthesis held the largest market share in 2023 due to its high efficiency and widespread application.
- In terms of application, the market is classified into research & development, diagnostics, and therapeutics. The research & development segment accounted for the largest revenue share, contributing 63.10% to the overall market, reflecting the growing demand for synthetic DNA in scientific and industrial research.
- Among end users, biopharmaceutical companies dominated the market in 2023, driven by increased investments in synthetic biology and precision medicine.
- Geographically, North America led the global market, capturing a share of 39.7% in 2023, supported by advanced research infrastructure and significant industry presence.
Segmentation Analysis
- Service Analysis: In 2023, the oligonucleotide synthesis segment dominated the market with a 54.8% share, driven by its essential role in genetic testing, diagnostics, synthetic biology, and gene editing. These molecules, used as primers and probes, are produced through efficient base-pair assembly. The adoption of automated synthesizers and high-throughput systems has enhanced production scalability and reduced costs, further boosting market demand across research and clinical laboratories.
- Method Analysis: Solid phase synthesis accounted for a significant market share in 2023 due to its precision and reliability in constructing DNA sequences. This method involves building DNA strand by strand on solid supports, ensuring controlled and automated synthesis. Its advantages include minimal error rates, high yield, and compatibility with custom sequence design. As a cost-effective and scalable technique, it is widely adopted in both academic and industrial settings for routine and advanced DNA applications.
- Application Analysis: The research & development segment led the application landscape with a 63.10% revenue share in 2023, driven by its foundational role in biotechnology innovation and pharmaceutical discovery. R&D activities rely heavily on synthetic DNA for developing new technologies, testing hypotheses, and engineering novel biological solutions. The rising need for customized DNA sequences to support drug discovery, genetic studies, and therapeutic development continues to accelerate demand within this segment.
- End-use Analysis: The biopharmaceutical companies segment witnessed significant growth in 2023, driven by the increasing use of synthesized DNA in the development of advanced therapeutics. These companies utilize synthetic DNA for creating targeted treatments, supporting the rise of precision medicine. Growth is further supported by regulatory approvals and commercialization of gene-based therapies. Notably, in January 2024, the U.S. FDA approved a gene therapy by Vertex Pharmaceuticals and CRISPR Therapeutics for sickle cell disease, highlighting the sector’s ongoing commitment to innovation and clinical application of synthetic DNA.
Market Segments
By Service
- Oligonucleotide synthesis
- Standard oligonucleotide synthesis
- Custom oligonucleotide synthesis
- Gene synthesis
- Custom gene synthesis
- Gene library synthesis
By Method
- Solid phase synthesis
- PCR-based enzyme synthesis
- CHIP-based DNA synthesis
By Application
- Research and Development
- Diagnostics
- Therapeutics
By End-use
- Biopharmaceutical companies
- Academic and research institutes
- Contract research organizations
Regional Analysis
North America dominated the DNA synthesis market in 2023, accounting for a leading revenue share of 39.7%. This growth is primarily attributed to the rising prevalence of genetic and chronic diseases, increasing patient awareness regarding personalized treatments, and the growing demand for early diagnosis and precision medicine. Technological advancements and substantial investments by life sciences companies and government agencies further support regional market growth.
For example, in March 2024, Elegen’s ENFINIA DNA technology enabled the rapid delivery of high-complexity DNA within ten business days. Additionally, growing research in personalized medicine and the widespread adoption of single-cell analysis tools continue to accelerate market expansion in fields such as oncology, immunology, and neuroscience.
Asia Pacific is projected to register the fastest compound annual growth rate (CAGR) over the forecast period. The region’s market growth is driven by ongoing improvements in healthcare infrastructure and advancements in DNA-based molecular biology applications. Increasing investments in synthetic DNA manufacturing facilities are addressing growing regional demand.
Furthermore, collaborations with local distributors are enhancing market reach. Notably, in April 2022, DNA Script entered into a distribution agreement with companies such as Premas Life Sciences Pvt. Ltd., Cold Spring Biotech Corp., Research Instruments Pte. Ltd., and Bio-Medical Science Co. Ltd. to expand access to its SYNTAX systems the world’s first enzymatic DNA synthesis (EDS)-based DNA printer across key Asian markets.
Emerging Trends
- Array Based Parallel Synthesis: The adoption of array based platforms has enabled the simultaneous production of over 10 distinct DNA sequences, markedly improving throughput and reducing per base costs through massive parallelization.
- High Fidelity PCR Based Assembly: The PCR based two step DNA synthesis (PTDS) method supports rapid construction of long DNA fragments (up to 5–6 kb) in just 5–7 days, with error rates lowered by the use of high fidelity polymerases.
- Cost Reduction Initiatives: Efforts are underway to close the “read write” cost gap, with DNA data storage applications targeting synthesis costs as low as US$0.01 per base pair.
- Long Range Construct Development: The maximum length of synthetic DNA constructs has grown from ~75 bp in the 1970s to records exceeding 582,970 bp today, reflecting advances in both chemistry and assembly techniques.
- Enzymatic Synthesis Advances: Novel enzymatic approaches are being explored to complement or replace phosphoramidite chemistry, promising milder reaction conditions and further reductions in error rates.
Use Cases
- Gene Therapy and Synthetic Vaccines: Custom DNA fragments of 2–6 kb (e.g., the 2,382 bp vip3a gene or the 5,367 bp CrtEBWY gene) are routinely synthesized for development of gene therapies and next generation vaccines.
- Diagnostic Oligonucleotides: Short DNA probes (20–60 nt) are mass produced for PCR and qPCR assays. Laboratories can synthesize tens of oligos in parallel, enabling rapid test development.
- DNA Data Storage: Synthetic DNA is leveraged as an ultra dense medium for digital archiving, addressing a projected global data storage demand of 1.75×10¹GB by 2025 while offering millennia long stability.
- Synthetic Biology Research: DNA synthesis underpins the design–build–test–learn cycle in synthetic biology, with custom genetic circuits and biosynthetic pathways spanning tens of kilobases assembled to probe biological functions.
- Biomedical Nanotechnology: Precisely folded DNA nanostructures are synthesized for cell surface engineering, facilitating targeted drug delivery and real time biosensing at the molecular level.
Conclusion
The DNA synthesis market is rapidly advancing, driven by innovations in gene editing, diagnostics, therapeutics, and synthetic biology. With a strong 2023 market performance and a projected CAGR of 15.5%, the sector is poised for substantial growth through 2033. Technological improvements such as high-fidelity PCR, enzymatic synthesis, and cost-reduction strategies are enhancing accessibility and scalability.
Regional expansion, particularly in North America and Asia Pacific, is further supported by strong research infrastructure and strategic collaborations. As demand for precision medicine, genetic engineering, and data storage grows, DNA synthesis will remain a critical enabler of progress across healthcare and biotechnology.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
